ASSFN Society News
Paolo Mazzone, William A. Friedman(Tufts University), Venetsana Kyriazopoulou, Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center), Daniel E. Lumsden, Eugenio Scarnati, John‐Stuart Brittain, Elli Markaki, Mariachiara Sensi(University of Ferrara), R. Quatrale(Ospedale dell' Angelo), Constantine Constantoyannis, Angelo Insola(Università Campus Bio-Medico), John Ellul(General University Hospital of Patras), Patric Blomstedt, Eftichia Trachani, David Ferson, Keyoumars Ashkan(Haywards Heath Hospital), J. Bridger Cox, Natasha Hulse, Anastasia Theodoropoulou(General University Hospital of Patras), Jean‐Pierre Lin(Instituto de Investigación Sanitaria La Fe), Nicolas Reyns(Centre National de la Recherche Scientifique), Sujit S. Prabhu(The University of Texas MD Anderson Cancer Center), Sudhakar Tummula, Jamal Carter, Marcos Dellaretti(Grupo Santa Casa de Belo Horizonte), Yueh‐Yun Chi(University of Southern California), Stefano Sposato, Ramesh Chelvarajah(University Hospitals Birmingham NHS Foundation Trust), Tipu Z. Aziz(University of Oxford), E. Granieri, Margaret Kaminska, Ned Jenkinson(University of Oxford), Michele Alessandro Cavallo(University of Ferrara), Ganesh Rao, Francesco Latini, Silvio Sarubbo(Provincia Autonoma di Trento), Hjálmar Bjartmarz(Skåne University Hospital), Richard Selway, Sebastião Gusmão(Universidade Federal de Minas Gerais), Maryam Rahman(University of Florida), Michael C. Samuel, Stephen L. Hicks, Júlio Leonardo Barbosa Pereira(Santa Casa Hospital), Robert H. Schapiro, S. Blond, François Dubois(Hôpital Roger Salengro), Zinovia Kefalopoulou(University College London), Christopher Kennard(Geisinger Medical Center), Gustavo Touzet(Hôpital Roger Salengro)
Cited by 0
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994